Acute Myeloid Leukemia and Menin-Targeted Therapy
Clinical research in relapsed and/or refractory acute myeloid leukemia and genetically defined AML subtypes, with emphasis on NPM1-mutated and KMT2A-rearranged disease.
- Relapsed/Refractory AML
- NPM1-mutated AML
- KMT2A-rearranged AML
- MEIS1-associated biology
Interest extends to menin inhibition and combination approaches in both newly diagnosed and previously treated myeloid malignancies.
Acute Lymphoblastic Leukemia
Research activity includes KMT2A-rearranged acute lymphoblastic leukemia, reflecting focus on hematologic cancers driven by specific genomic alterations.
- KMT2A-r ALL
- Genetically defined leukemia
The therapeutic interest centers on targeted treatment options for aggressive lymphoid malignancies with KMT2A-related biology.
Solid Tumors
The sponsor also funds studies in advanced solid tumors, including several gastrointestinal and thoracic cancer types.
- Colorectal cancer
- Pancreatic ductal adenocarcinoma
- Non-small cell lung cancer
- Renal cell carcinoma
These programs indicate interest in molecularly informed treatment strategies across difficult-to-treat solid malignancies.
